Clinical trials: Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Human Immunodeficiency Virus
Tissue Drug Levels of HIV Medications
The aim of this study is to find out why HIV continues to make copies in people taking HIV drugs. The investigators want to know if the medications most people use to treat HIV get into the lymphatic tissue where HIV persists.
- Trial name
- NCT01490346
- Testing
- Initiation of anti-retroviral therapy
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Minnesota
HIV Infections
Phase I Study of HIV Adenoviral Vector Vaccine in Healthy Subjects Using Needle or Biojector Injection
This study will compare the immune response and side effects of an experimental HIV vaccine given by two different methods of administration by needle injection or by use of a needle-free device called the Biojector 2000…
- Trial name
- NCT00709605
- Testing
- VRC-HIVADV014-00-VP
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
BASIC: Boosted Atazanavir or Saquinavir Induced Lipid Changes
The purpose of this study is to assess differences in changes in plasma lipids between patients on saquinavir/ritonavir or atazanavir/ritonavir in combination with tenofovir disoproxil fumarate and emtricitabine as a first-line…
- Trial name
- NCT00389402
- Testing
- saquinavir/ritonavir, atazanavir/ritonavir
- Where
- Netherlands
- Volunteers
- 120 people
- Sponsor
- International Antiviral Therapy Evaluation Center
HIV-1-infection
Combining TLR9 Agonist With bNAbs for Reservoir Reduction and Immunological Control of HIV
This study is designed to evaluate the safety and efficacy of lefitolimod and 3BNC117/10-1074 in HIV-1-infected individuals on ART and during ATI as intervention to reduce the HIV-1 reservoir
- Trial name
- TITAN (NCT03837756)
- Testing
- Saline, Lefitolimod, 3BNC117 and 10-1074
- Where
- 8 sites in United States, Australia and 2 more
- Volunteers
- 47 people
- Sponsor
- University of Aarhus
HIV Infections
Pilot Study Evaluating Interruption of Enfuvirtide (Fuzeon, T20) in Patients With Enfuvirtide Resistance
The goal of this study is to examine whether enfuvirtide (T20, Fuzeon) has continued anti-HIV activity in patients experiencing an incomplete virologic response to an enfuvirtide-based regimen.
- Trial name
- NCT00187551
- Testing
- Interruption of enfuvirtide, enfuvirtide interrupton
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of California, San Francisco
HIV-1
Third-Generation CAR-T-cell Therapy in Individuals With HIV-1 Infection
To evaluate the safety of autologous CAR-T-cell therapy in individuals lived with HIV-1 infection, CAR T cells are infused after ex vivo expansion and transduction with lentiviral vectors encoding a broadly neutralizing HIV-1…
- Trial name
- TCTIWHI (NCT04863066)
- Testing
- CAR-T cells
- Where
- China
- Volunteers
- 8 people
- Sponsor
- Beijing 302 Hospital
HIV Infection
Pilot Study of Raltegravir Lipodystrophy IISP
The substitution of raltegravir for the NRTIs will result in some reversal of the long term adverse effect of lipodystrophy (specifically peripheral lipoatrophy) that is associated with the chronic use of NRTIs.
- Trial name
- NCT01164605
- Testing
- Raltegravir
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Southern California Institute for Research and Education
HIV Infections
Study Evaluating Vaccine in Adults With HIV
The main purpose of this study is to learn whether the study vaccine and the adjuvants(drugs that are used to help immune response) have an acceptable safety profile in treating individuals with HIV.
- Trial name
- NCT00195312
- Testing
- HIV-1 gag DNA (formulated with bupivacaine), IL-15 DNA (formulated with bupivacaine), IL-12 DNA (formulated with bupivacaine)
- Where
- 13 sites in United States, Germany and 1 more
- Volunteers
- 91 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
HIV Infections
Effectiveness of Adding Interleukin-2 to Anti-HIV Drugs in Patients Recently Infected With HIV
The purpose of this study is to see whether taking interleukin-2 (IL-2) and other anti-HIV drugs affects the course of HIV disease in patients with primary HIV infection (the time period that immediately follows infection with…
- Trial name
- NCT00006441
- Testing
- Lamivudine/Zidovudine, Nelfinavir mesylate, Aldesleukin
- Where
- 2 sites in United States
- Volunteers
- 398 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Human Immunodeficiency Virus Infection
Viral and Antiretroviral Dynamics in HIV-1 Mother-to-Child Transmission Fluids
More than 150,000 babies became infected with HIV in 2015 alone. When HIV drugs are started before or early in pregnancy, HIV positive women can give birth to HIV negative baby.
- Trial name
- VADICT (NCT03284645)
- Testing
- Tenofovir Disoproxil Fumarate (TDF) 300 mg + Lamivudine (3TC) 300 mg + Efavirenz (EFV) 600 mg, Abacavir (ABC) 600 mg + Lamivudine (3TC) 300 mg + Efavirenz (EFV) 600 mg, Zidovudine (AZT) 300 mg + Lamivudine (3TC) 150 mg twice daily + Efavirenz (EFV) 600 mg once daily
- Where
- 4 sites in Nigeria
- Volunteers
- 194 people
- Sponsor
- Obafemi Awolowo University
HIV Infection
A Study of the Safety, Tolerability, and Antiretroviral Activity of Raltegravir (MK-0518) in Combination With Other Antiretroviral Therapies in Russian Children and Adolescents Infected With Human Immunodeficiency Virus (HIV-1) (MK-0518-248)
This multicenter, open-label, noncomparative study evaluates two oral formulations of raltegravir (MK-0518, film-coated tablet and chewable tablet) in combination with other antiretroviral agents for safety, tolerability, and…
- Trial name
- NCT01717287
- Testing
- Raltegravir Film-coated Tablet, Raltegravir Chewable Tablet, Other Anti-Retroviral Therapy
- Volunteers
- 32 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV-1-infection
Dose Escalation Safety Study of TMB-365 in HIV-1 Infected Participants
This study will evaluate the safety and behavior in the body of the experimental drug TMB-365 in people with HIV-1 infection. This will be the first test of TMB-365 in humans.
- Trial name
- NCT04027387
- Testing
- TMB-365
- Where
- 6 sites in United States, Puerto Rico
- Volunteers
- 24 people
- Sponsor
- TaiMed Biologics Inc.
HIV-1-infection
Optimization of HIV-1 DNA Genotyping by High Throughput Sequencing to Document Antiretroviral Resistant Mutations
The analysis of HIV resistance to antiretrovirals (Sanger sequencing on RNA) is difficult when the viral load is undetectable or during therapeutic breaks.
- Trial name
- Mutapro (NCT03512795)
- Testing
- Blood samples
- Where
- France
- Volunteers
- 71 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
HIV-1-infection
Dolutegravir in Real Life in Lesotho
DO-REAL is an observational cohort study assessing the large-scale roll-out of the antiretroviral drug dolutegravir (DTG) in Lesotho.
- Trial name
- DO-REAL (NCT04238767)
- Testing
- Dolutegravir
- Where
- 2 sites in Lesotho
- Volunteers
- 1,433 people
- Sponsor
- Swiss Tropical & Public Health Institute
Human Immunodeficiency Virus Type 1 (HIV-1)
Bioequivalence Study of Individual Atazanavir and Cobicistat Compared With Atazanavir in Fixed-dose Combination With Cobicistat
The purpose of the study is to compare the pharmacokinetics and bioequivalence of atazanavir in a fixed-dose combination with cobicistat with that of atazanavir coadministered with cobicistat as single agents.
- Trial name
- Atazanavir (NCT01837719)
- Testing
- Atazanavir, Cobicistat, Atazanavir/Cobicistat FDC
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
HIV-1 Infection
4 Consecutive Days on Treatment Followed by 3 Days Off Treatment, in HIV Patients
Evaluate after 48 weeks, the capacity of a weekly strategy of 4 consecutive days on treatment followed by 3 days off treatment, in HIV-1 treated patients with undetectable viral load for at least 12 months and continuous…
- Trial name
- ANRS162-4D (NCT02157311)
- Testing
- Four consecutive days on treatment and 3 days off
- Where
- 17 sites in France
- Volunteers
- 100 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Acquired Immunodeficiency Syndrome, HIV Infection
Home Treatment of HIV-Infected Patients With Interleukin-2 With or Without a Tumor Necrosis Factor Antagonist
Patients enrolled in NIH protocol 95-I-0133 at the Clinical Center may participate in an extension phase of this study in which the drug prednisone will be eliminated from the treatment regimen.
- Trial name
- NCT00001475
- Testing
- IL-2 plus Anti-TNF or Thalidomide
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Human Immunodeficiency Virus (HIV) Infection
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment-Experienced HIV-1 Infected Patients
The purpose of this study is to learn more about the safety and tolerability of etravirine. Etravirine is a type of non-nucleoside reverse transcriptase inhibitor (NNRTI) which has shown high activity against wild-type human…
- Trial name
- NCT01422330
- Testing
- Etravirine
- Where
- 42 sites in United States, Argentina and 9 more
- Volunteers
- 211 people
- Sponsor
- Janssen R&D Ireland
HIV Infections
Safety and Effectiveness of PENNVAX-B Vaccine Alone, With Il-12, or IL-15 in Healthy Adults
The purpose of this study is to determine the safety, tolerability, and immune response to the DNA HIV vaccine, PENNVAX-B alone, in combination with IL-12, or with 2 different doses of IL-15.
- Trial name
- NCT00528489
- Testing
- PennVax B, IL-12, IL-15
- Where
- 8 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Study to Evaluate the Replacement of Reverse Transcriptase Nucleoside/Nucleotide Inhibitors by Nevirapine in Patients on Triple Treatment With Analogues Only
The purpose of this study is to evaluate the proportion of patients with viral load of HIV-1 < 50 copies after 48 weeks of follow-up after randomization to change or not to nevirapine.
- Trial name
- NCT00415090
- Testing
- Nevirapine
- Where
- 17 sites in Spain
- Volunteers
- 28 people
- Sponsor
- Hospital de Calella
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.